Coya Therapeutics announced on September 29, 2025, the completion of patient enrollment for an investigator-initiated, proof-of-concept, open-label study. This study evaluates low-dose IL-2 and CTLA4-Ig combination treatment in patients with mild to moderate Frontotemporal Dementia (FTD).
Following positive interim results announced in April 2025, an additional four patients were enrolled, bringing the total to nine FTD patients as planned. The trial is progressing according to the study protocol, and no serious adverse events or discontinuations due to safety issues have been reported.
Study completion is anticipated in the fourth quarter of 2025, with topline results to follow after database lock and data analysis. This milestone is crucial for advancing the development of a potential treatment for FTD, a devastating neurodegenerative disease with high unmet medical need.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.